Compare Illumina, Inc. (ILMN) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Taskus Inc — how do they compare? Illumina, Inc. trades at $274.69 (market cap $39.95B), while Taskus Inc trades at $8.08 (market cap $723.41M). The key difference: Illumina, Inc. is far larger — about 55.2× Taskus Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Taskus Inc for 34 Days on average.
| ILMN | TASK | |
|---|---|---|
Market Cap | $39.95B | $723.41M |
Volume | 3,169,503 | 201,303 |
Sector | Health | Technology |
52-Week High | $293.69 | $14.69 |
52-Week Low | $91.00 | $4.57 |
Typical Hold Time | 83 Days | 34 Days |
Enterprise Value | $41.31B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
TaskUs (TASK) trades at $8.06, up 2.15% today, with a bearish technical signal but strong fundamentals. Revenue reached $1.18 billion in 2025, with net income surging to $102.28 million and an 8.75% margin. The stock appears undervalued with a P/E of 6.8 and P/S of 0.6. Recent news highlights AI-driven growth offsetting legacy declines, with Q2 2026 earnings beating estimates.
The outlook is mixed: low valuation and AI expansion offer upside, but technical weakness and margin pressure from labor costs pose risks. Analysts are generally bullish with a $9.33 consensus target, implying 16% upside, though competitive and execution challenges remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
